Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.92 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5304867 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5292464 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL2371129 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5289574 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5285514 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5307289 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5297463 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5818453 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5287604 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL22806629 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272800-B1 | Detoxification of water containing onium compounds | BAKER HUGHES INC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2272800-A1 | Detoxification of water containing onium compounds | Baker Hughes Incorporated (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1766183-A1 | ENHANCEMENT MODIFIERS FOR GAS HYDRATE INHIBITORS | Baker Hughes Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2005116399-A1 | ENHANCEMENT MODIFIERS FOR GAS HYDRATE INHIBITORS | BAKER HUGHES INCORPORATED (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050261529-A1 | Enhancement modifiers for gas hydrate inhibitors | BAKER HUGHES INCORPORATED | 2005-11-24 | — | — | US | disclosed |
| EP-1362160-B1 | COMPOSITION AND METHOD FOR INHIBITION OF FORMATION OF GAS HYDRATES | BAKER HUGHES INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6841089-B2 | Detoxification of onium compounds | BAKER HUGHES INCORPORATED (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1456129-A2 | DETOXIFICATION OF WATER CONTAINING ONIUM COMPOUNDS | BAKER HUGHES INCORPORATED (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6723249-B2 | NEUTRALIZATION WITH ACID, SULFONATE | BAKER HUGHES INCORPORATED | 2004-04-20 | — | — | US | disclosed |
| EP-1362160-A1 | COMPOSITION AND METHOD FOR INHIBITION OF FORMATION OF GAS HYDRATES | BAKER HUGHES INCORPORATED (US) | 2003-11-19 | — | — | EP | disclosed |
| US-6620330-B2 | Removing pollutants from waste water streams | BAKER HUGHES INCORPORATED | 2003-09-16 | — | — | US | disclosed |
| US-20030146173-A1 | Detoxification of quaternary onium compounds with polycarboxylate-containing compound | BAKER HUGHES INCORPORATED | 2003-08-07 | — | — | US | disclosed |
| US-6596911-B2 | Providing a mixture comprising water and a hydrocarbon; and contacting with onium compound and amine salt for inhibiting the formation of the hydrocarbon hydrates | BAKER HUGHES INCORPORATION | 2003-07-22 | — | — | US | disclosed |
| US-20030116507-A1 | Detoxification of onium compounds | BAKER HUGHES INCORPORATED | 2003-06-26 | — | — | US | disclosed |
| WO-2003051781-A1 | DETOXIFICATION OF QUATERNARY ONIUM COMPOUNDS WITH POLYCARBOXYLATE CONTAINING COMPOUND | BAKER HUGHES INCORPORATED (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051776-A2 | DETOXIFICATION OF WATER CONTAINING ONIUM COMPOUNDS | BAKER HUGHES INCORPORATED (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002066785-A1 | COMPOSITION AND METHOD FOR INHIBITION OF FORMATION OF GAS HYDRATES | BAKER HUGHES INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020038063-A1 | Composition and method for inhibition of formation of gas hydrates | BAKER HUGHES INCORPORATED | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261529-A1 | Enhancement modifiers for gas hydrate inhibitors | AQP1, API5, IWS1 | SLC22A1 795/4885ALDH1A1 4364/4885TP53 1673/4885 |
| US-20020038063-A1 | Composition and method for inhibition of formation of gas hydrates | HDHD5, SHH, NOTUM | SLC22A1 2116/4885ALDH1A1 4272/4885TP53 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.